tranexamic acid has been researched along with Hematologic Diseases in 4 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 8.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders." | 8.89 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013) |
| "Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrum of bradykinin angioedemas." | 5.05 | [Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment]. ( Armengol, G; Boccon-Gibod, I; Bouillet, L; Coppo, P; Defendi, F; Du-Thanh, A; Fain, O; Gobert, D; Hardy, G; Javaud, N; Jeandel, PY; Launay, D; Panayotopoulos, V; Pelletier, F, 2020) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 4.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders." | 4.89 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gobert, D | 1 |
| Bouillet, L | 1 |
| Armengol, G | 1 |
| Coppo, P | 1 |
| Defendi, F | 1 |
| Du-Thanh, A | 1 |
| Hardy, G | 1 |
| Javaud, N | 1 |
| Jeandel, PY | 1 |
| Launay, D | 1 |
| Panayotopoulos, V | 1 |
| Pelletier, F | 1 |
| Boccon-Gibod, I | 1 |
| Fain, O | 1 |
| Cornelissen, LL | 1 |
| Caram-Deelder, C | 1 |
| Meier, RT | 1 |
| Zwaginga, JJ | 1 |
| Evers, D | 1 |
| Wardrop, D | 1 |
| Estcourt, LJ | 2 |
| Brunskill, SJ | 2 |
| Doree, C | 2 |
| Trivella, M | 1 |
| Stanworth, S | 1 |
| Murphy, MF | 2 |
| Desborough, M | 1 |
| Hopewell, S | 1 |
| Stanworth, SJ | 1 |
3 reviews available for tranexamic acid and Hematologic Diseases
| Article | Year |
|---|---|
[Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment].
Topics: Angioedema; Angioedemas, Hereditary; Bradykinin; Chemoprevention; Comorbidity; Diagnosis, Differenti | 2020 |
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2013 |
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2016 |
1 other study available for tranexamic acid and Hematologic Diseases
| Article | Year |
|---|---|
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.
Topics: Clinical Decision-Making; Disease Management; Disease Susceptibility; Health Care Surveys; Hematolog | 2021 |